scholarly journals 53QUALITY OF CARE IN VERY OLD PATIENTS WITH TYPE 2 DIABETES MELLITUS: DISPARITIES BETWEEN PATIENTS MANAGED WITH LIFE STYLE INTERVENTIONS ONLY AND THOSE TREATED WITH ANTIDIABETIC MEDICATIONS

2015 ◽  
Vol 44 (suppl 2) ◽  
pp. ii16-ii16
Author(s):  
S. Hamada ◽  
M.C. Gulliford
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Life Style ◽  
Old Patients ◽  
Very Old ◽  
Very Old Patients

Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure

2021 ◽  
Author(s):  
Luis M. Pérez‐Belmonte ◽  
Jaime Sanz‐Cánovas ◽  
Mercedes Millán‐Gómez ◽  
Julio Osuna‐Sánchez ◽  
Almudena López‐Sampalo ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Acute Heart Failure ◽  
Old Patients ◽  
Very Old ◽  
Clinical Benefits ◽  
Very Old Patients

Comorbidity in Very Old Adults with Type 2 Diabetes Mellitus

2013 ◽  
Vol 61 (6) ◽  
pp. 1028-1029 ◽  
Author(s):  
Justin Y. Chow ◽  
Jason X. Nie ◽  
Christopher Shawn Tracy ◽  
Li Wang ◽  
Ross E. G. Upshur
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Very Old ◽  
Old Adults

scholarly journals Association between prior cardiometabolic therapy and in-hospital mortality in very old patients with type 2 diabetes mellitus hospitalized due to COVID-19. A nationwide observational study in Spain

2020 ◽  
Author(s):  
Jose Manuel Ramos-Rincón ◽  
Luis M Pérez-Belmonte ◽  
Francisco Javier Carrasco-Sánchez ◽  
Sergio Jansen-Chaparro ◽  
Mercedes De-Sousa-Baena ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Hospital Mortality ◽  
Angiotensin Receptor Blockers ◽  
Converting Enzyme Inhibitors ◽  
Old Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

Abstract Background Advanced age and diabetes are both associated with poor prognosis in COVID-19. However, the effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well-known. This work aims to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥ 80 years with type 2 diabetes mellitus hospitalized for COVID-19. Methods We conducted a nationwide, multicenter, retrospective, observational study in patients ≥ 80 years with type 2 diabetes mellitus and COVID-19 hospitalized in 160 Spanish hospitals between March 1 and May 29, 2020 who were included in the SEMI-COVID-19 Registry. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis were performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. The regression analysis values were expressed as adjusted odds ratios (AOR) with a 95% confidence interval (CI). In order to select the variables, the forward selection Wald statistic was used. Discrimination of the fitted logistic model was assessed via a receiver operating characteristic (ROC) curve. The Hosmer-Lemeshow test for logistic regression was used to determine the model’s goodness of fit. Results Of the 2,763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (AOR 0.502, 95% CI 0.309–0.815, p = 0.005) and angiotensin receptor blockers (AOR 0.454, 95% CI 0.274–0.759, p = 0.003) were independent protectors against in-hospital mortality whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI 1.092–2.842, p = 0.020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors and statins showed neutral association with in-hospital mortality. The model showed an area under the curve of 0.788. Conclusions We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with type 2 diabetes mellitus hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers may reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors and statins seem to have a neutral effect; and acetylsalicylic acid may be associated with excess mortality.

Sign in / Sign up

Export Citation Format

Share Document